Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

OLMA

Olema Pharmaceuticals Inc

Feb 06 • 04:00PM ET

25.36

+0.35 1.40 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN GILD VRTX REGN BIIB ONC INCY NBIX EXEL ACAD

| Held by: VTI IWM XBI IWN IBB VXF VTWO SCHA DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	16.13%	Shs Outstand	68.65M	Perf Week	-1.40%
Market Cap	1.99B	Forward P/E	-	EPS next Y	-2.24	Insider Trans	-6.21%	Shs Float	65.97M	Perf Month	-6.32%
Enterprise Value	1.67B	PEG	-	EPS next Q	-0.52	Inst Own	74.24%	Short Float	13.79%	Perf Quarter	218.99%
Income	-149.96M	P/S	-	EPS this Y	12.92%	Inst Trans	-2.50%	Short Ratio	2.40	Perf Half Y	437.29%
Sales	0.00M	P/B	5.66	EPS next Y	-17.08%	ROA	-51.48%	Short Interest	9.10M	Perf YTD	1.44%
Book/sh	4.48	P/C	6.06	EPS next 5Y	-3.01%	ROE	-59.22%	52W High	36.26 -30.06%	Perf Year	282.50%
Cash/sh	4.18	P/FCF	-	EPS past 3/5Y	-7.01% -83.00%	ROIC	-48.25%	52W Low	2.86 786.71%	Perf 3Y	420.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.91% 7.11%	Perf 5Y	-39.27%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.23%	Oper. Margin	-	ATR (14)	1.90	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.68	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.03	EPS Q/Q	18.40%	SMA20	-4.40%	Beta	1.93	Target Price	45.60
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-7.77%	Rel Volume	0.25	Prev Close	25.01
Employees	96	LT Debt/Eq	0.01	Earnings	Nov 10 BMO	SMA200	111.19%	Avg Volume	3.79M	Price	25.36
IPO	Nov 19, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.24% -	Trades		Volume	962,217	Change	1.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Piper Sandler	Overweight	$40
Oct-08-25	Initiated	Guggenheim	Buy	$20
Aug-12-25	Reiterated	Citigroup	Buy	$20 → $21
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

Feb-04-26 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
Feb-03-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-26 04:01PM	Olema Oncology Announces Departure of Chief Operating and Financial Officer (GlobeNewswire)
09:47AM	LifeSci Capital Reiterates a Buy on Olema Pharmaceuticals (OLMA) (Insider Monkey)
Jan-21-26 05:59AM	Piper Sandler Puts its Weight Behind 2 Strong Buy Cancer Stocks (TipRanks)
04:30PM	Loading…
Jan-05-26 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:19AM	Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT (Insider Monkey)
Dec-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-25 05:45PM	This strategist is 'following the money' on these stock picks (Yahoo Finance Video) +8.11%
Nov-21-25 04:30PM	Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire) +5.27%
Nov-20-25 04:01PM	Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +13.28%
Nov-19-25 11:50AM	Olema Pharmaceuticals Has Nearly Tripled on Cancer Drug Hopes. How Should You Play OLMA Stock Here? (Barchart)
07:00AM	Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock (GlobeNewswire)
Nov-18-25 04:51PM	Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +136.38%
04:21PM	Loading…
04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
09:20AM	Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% (Investor's Business Daily)
Nov-10-25 07:00AM	Olema Oncology Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.13%
Oct-30-25 04:30PM	Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 (GlobeNewswire)
Oct-18-25 03:00AM	Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 (GlobeNewswire)
Oct-16-25 04:33PM	Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential (Insider Monkey) -7.43%
Oct-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-25 11:41AM	Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) (Insider Monkey)
Sep-12-25 10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
Sep-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 07:00AM	Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer (GlobeNewswire) +18.50%
Aug-20-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
01:15AM	Loading…
Aug-13-25 01:15AM	Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals (Insider Monkey)
Aug-11-25 04:01PM	Olema Oncology Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire) +16.19%
Aug-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.43%
May-28-25 07:00AM	Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting (GlobeNewswire)
May-21-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
09:55AM	Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? (Zacks)
May-13-25 04:01PM	Olema Oncology Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-09-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
Apr-25-25 01:00PM	Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 (GlobeNewswire)
Apr-24-25 09:55AM	Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet (Zacks)
Apr-10-25 09:35AM	After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA) (Zacks) +8.25%
Apr-08-25 04:25PM	Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market (Seeking Alpha)
Apr-02-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-25-25 04:31PM	Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-18-25 04:01PM	Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire) -6.97%
Mar-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-25 04:30PM	Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 07:00AM	Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Feb-04-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46%
Feb-03-25 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-03-25 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.75% -6.62%
Jan-02-25 07:00AM	Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-24 07:00AM	Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-09-24 07:00AM	Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor (GlobeNewswire) -9.67%
Dec-03-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:17AM	Novartis and Olema expand alliance with $250m to boost breast cancer trials (Pharmaceutical Technology)
Dec-02-24 07:00AM	Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement (GlobeNewswire)
Nov-25-24 05:30PM	Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium (GlobeNewswire) +9.09%
Nov-24-24 07:27PM	Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors (PR Newswire)
Nov-12-24 04:01PM	Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.28%
Nov-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 04:44PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024 (GlobeNewswire)
Oct-09-24 07:00AM	Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 04:49PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 07:00AM	Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:02PM	Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -9.90%
Aug-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.22%
Aug-01-24 08:50AM	Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why (Zacks)
Jul-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
Jun-04-24 04:28PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.96%
May-28-24 07:03AM	Olema Oncology to Participate in Upcoming Investor Conferences in June (GlobeNewswire)
May-15-24 07:01AM	Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress (GlobeNewswire)
May-08-24 10:58PM	OLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace) -9.31%
04:02PM	Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:02AM	Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire) +5.96%
May-02-24 04:37PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-24 07:02AM	Olema Oncology to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-08-24 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference (GlobeNewswire) +5.33%
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Apr-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-24 04:03PM	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.62%
Mar-06-24 07:03AM	Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors (GlobeNewswire)
Mar-04-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.01%
Feb-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:12AM	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate (GlobeNewswire)
Jan-02-24 04:01PM	Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 10:59AM	Hedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and More (Insider Monkey)
Dec-05-23 12:27PM	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies (GlobeNewswire) -15.34%
Dec-04-23 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-23 09:30AM	Top Stocks for December 2023 (Investopedia)
Nov-28-23 05:10PM	Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Jan 20 '26	Sale	26.88	10,000	268,800	727,770	Jan 21 09:00 PM
Harmon Cyrus	Director	Jan 20 '26	Proposed Sale	26.88	10,000	268,763		Jan 20 04:13 PM
Harmon Cyrus	Director	Jan 14 '26	Sale	29.12	3,489	101,600	737,770	Jan 16 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 15 '26	Sale	28.73	100,000	2,873,000	139,727	Jan 15 09:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 13 '26	Sale	28.01	3,822	107,054	239,727	Jan 15 09:00 PM
Kovacs Shane William Charles	Officer	Jan 15 '26	Proposed Sale	28.73	100,000	2,873,215		Jan 15 04:22 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Option Exercise	4.87	50,000	243,500	592,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 14 '26	Sale	28.87	50,000	1,443,651	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 13 '26	Sale	27.60	50,000	1,380,178	542,761	Jan 14 09:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Jan 12 '26	Sale	28.34	10,000	283,400	144,846	Jan 14 09:30 PM
Harmon Cyrus	Director	Jan 14 '26	Proposed Sale	29.12	3,489	101,603		Jan 14 04:20 PM
Myles David C.	Officer	Jan 14 '26	Proposed Sale	28.87	50,000	1,443,631		Jan 14 04:13 PM
Kovacs Shane William Charles	Officer	Jan 13 '26	Proposed Sale	28.01	3,822	107,069		Jan 13 04:49 PM
Myles David C.	Officer	Jan 13 '26	Proposed Sale	27.60	50,000	1,380,113		Jan 13 04:12 PM
Myles David C.	Officer	Jan 12 '26	Proposed Sale	28.34	10,000	283,363		Jan 12 12:53 PM
Harmon Cyrus	Director	Dec 22 '25	Sale	28.53	2,881	82,195	741,259	Dec 29 09:55 PM
CLARK IAN T	Director	Dec 19 '25	Option Exercise	4.61	264,800	1,219,544	264,800	Dec 23 09:42 PM
CLARK IAN T	Director	Dec 19 '25	Sale	29.73	264,800	7,873,109	0	Dec 23 09:42 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Dec 19 '25	Sale	30.46	51,000	1,553,544	551,881	Dec 23 09:41 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Option Exercise	14.07	50,000	703,392	153,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Option Exercise	15.25	40,000	610,000	173,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Option Exercise	7.02	50,000	351,000	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 22 '25	Sale	28.04	100,000	2,804,000	53,997	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 23 '25	Sale	27.66	99,509	2,752,419	4,488	Dec 23 09:40 PM
Zojwalla Naseem	Chief Medical Officer	Dec 19 '25	Sale	28.20	70,000	1,973,729	103,997	Dec 23 09:40 PM
Zojwalla Naseem	Officer	Dec 23 '25	Proposed Sale	27.66	99,509	2,752,165		Dec 23 01:31 PM
Harmon Cyrus	Officer	Dec 22 '25	Proposed Sale	28.53	2,881	82,182		Dec 22 04:09 PM
Zojwalla Naseem	Officer	Dec 22 '25	Proposed Sale	28.04	100,000	2,804,039		Dec 22 02:14 PM
Myles David C.	Officer	Dec 19 '25	Proposed Sale	30.46	51,000	1,553,447		Dec 19 04:33 PM
Zojwalla Naseem	Officer	Dec 19 '25	Proposed Sale	28.19	70,000	1,973,561		Dec 19 04:29 PM
CLARK IAN T	Director	Dec 19 '25	Proposed Sale	29.73	264,800	7,873,502		Dec 19 02:35 PM
RAPPAPORT ANDREW	Director	Nov 21 '25	Option Exercise	0.39	35,868	13,989	35,868	Nov 25 06:00 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.33	10,000	83,300	744,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.04	10,000	80,400	754,140	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Sale	8.32	3,086	25,676	117,028	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 16 '25	Sale	8.08	1,914	15,465	120,114	Sep 18 09:30 PM
Harmon Cyrus	Director	Sep 18 '25	Proposed Sale	8.33	13,086	108,978		Sep 18 02:08 PM
Harmon Cyrus	Director	Sep 16 '25	Proposed Sale	8.04	11,914	95,827		Sep 16 04:39 PM

Open in Screener

KYTX

Kyverna Therapeutics Inc

Feb 06 • 04:00PM ET

7.93

+0.66 9.08 %

Healthcare • Biotechnology • USA • NASD

KYTX Kyverna Therapeutics Inc daily Stock Chart

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI VXF IBB SURI SCHA IWC AVSC DFAS SCHB DFAC

Index	-	P/E	-	EPS (ttm)	-3.72	Insider Own	38.64%	Shs Outstand	43.79M	Perf Week	-1.00%
Market Cap	453.04M	Forward P/E	-	EPS next Y	-3.47	Insider Trans	1.11%	Shs Float	35.05M	Perf Month	-8.85%
Enterprise Value	286.92M	PEG	-	EPS next Q	-0.85	Inst Own	28.80%	Short Float	9.72%	Perf Quarter	14.10%
Income	-160.99M	P/S	-	EPS this Y	-10.93%	Inst Trans	-0.81%	Short Ratio	2.29	Perf Half Y	139.58%
Sales	0.00M	P/B	2.29	EPS next Y	6.11%	ROA	-61.17%	Short Interest	3.41M	Perf YTD	-15.64%
Book/sh	3.47	P/C	2.65	EPS next 5Y	1.16%	ROE	-70.82%	52W High	13.67 -41.99%	Perf Year	142.51%
Cash/sh	3.00	P/FCF	-	EPS past 3/5Y	-75.88% -	ROIC	-105.03%	52W Low	1.78 345.51%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.96% 9.12%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-21.22%	Oper. Margin	-	ATR (14)	0.80	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.16	EPS Q/Q	-6.05%	SMA20	-8.04%	Beta	3.40	Target Price	29.60
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-5.73%	Rel Volume	0.53	Prev Close	7.27
Employees	112	LT Debt/Eq	0.01	Earnings	Nov 12 AMC	SMA200	48.36%	Avg Volume	1.49M	Price	7.93
IPO	Feb 08, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.47% -	Trades		Volume	782,872	Change	9.08%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Feb-03-26 08:00AM	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer (GlobeNewswire)
Jan-12-26 08:00AM	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -7.30%
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-17-25 09:24AM	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire) -32.52%
10:10AM	Loading…
Dec-16-25 10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks) -5.36%
09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.23%
06:30AM	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (GlobeNewswire)
03:41AM	Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease (BioPharma Dive)
Dec-14-25 02:30PM	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome (GlobeNewswire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart) +5.02%
Nov-12-25 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.60%
Nov-10-25 08:00AM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-03-25 08:00AM	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance (GlobeNewswire)
06:30AM	Loading…
Oct-29-25 06:30AM	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 (GlobeNewswire) -5.78%
Oct-25-25 11:00AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis (GlobeNewswire) -6.58%
Oct-17-25 09:59AM	Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout (Insider Monkey) -5.42%
Sep-24-25 09:05AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS (GlobeNewswire)
Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
04:02PM	Loading…
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:43 AM
Westlake BioPartners Opportuni	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:42 AM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17 08:30 PM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17 08:30 PM
KAREN WALKER	Officer	Dec 15 '25	Proposed Sale	8.78	23,998	210,702		Dec 15 04:16 PM

Open in Screener

ANNX

Annexon Inc

Feb 06 • 04:00PM ET

5.73

+0.10 1.78 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX RARE CRSP NTLA EDIT ALLO BLUE FOLD MYO SGMO

| Held by: VTI IWM XBI VXF IBB IWN SCHA VTWO VHT DWAS

Index	RUT	P/E	-	EPS (ttm)	-1.41	Insider Own	11.45%	Shs Outstand	144.73M	Perf Week	-8.17%
Market Cap	829.29M	Forward P/E	-	EPS next Y	-1.07	Insider Trans	16.74%	Shs Float	128.16M	Perf Month	3.62%
Enterprise Value	667.51M	PEG	-	EPS next Q	-0.32	Inst Own	67.50%	Short Float	14.39%	Perf Quarter	90.37%
Income	-208.88M	P/S	-	EPS this Y	-37.03%	Inst Trans	1.89%	Short Ratio	6.47	Perf Half Y	141.77%
Sales	0.00M	P/B	4.09	EPS next Y	22.79%	ROA	-68.11%	Short Interest	18.44M	Perf YTD	14.14%
Book/sh	1.40	P/C	4.39	EPS next 5Y	6.92%	ROE	-83.99%	52W High	7.18 -20.19%	Perf Year	54.86%
Cash/sh	1.30	P/FCF	-	EPS past 3/5Y	33.38% -0.09%	ROIC	-112.57%	52W Low	1.28 345.91%	Perf 3Y	-20.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.36% 7.71%	Perf 5Y	-73.97%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-35.62%	Oper. Margin	-	ATR (14)	0.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.42	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.84	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.42	EPS Q/Q	-47.97%	SMA20	-8.47%	Beta	1.16	Target Price	14.71
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	5.82%	Rel Volume	0.72	Prev Close	5.63
Employees	100	LT Debt/Eq	0.15	Earnings	Nov 10 AMC	SMA200	75.04%	Avg Volume	2.85M	Price	5.73
IPO	Jul 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.41% -	Trades		Volume	2,060,082	Change	1.78%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-23-25	Initiated	Chardan Capital Markets	Buy	$16
Mar-01-24	Upgrade	JP Morgan	Neutral → Overweight	$11
Dec-21-23	Upgrade	BofA Securities	Neutral → Buy	$4 → $6
Oct-30-23	Initiated	Wells Fargo	Overweight	$11
May-26-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $3
May-25-23	Downgrade	JP Morgan	Overweight → Neutral	$19 → $9
Sep-16-22	Initiated	Jefferies	Buy	$12
Sep-09-22	Initiated	BTIG Research	Buy	$15
Nov-30-21	Initiated	H.C. Wainwright	Buy	$40
Sep-23-21	Initiated	Cantor Fitzgerald	Overweight	$40
Jan-26-21	Initiated	Needham	Buy	$37
Aug-18-20	Initiated	JP Morgan	Overweight	$33
Aug-18-20	Initiated	Cowen	Outperform
Aug-18-20	Initiated	BofA Securities	Buy	$33

Show Previous Ratings

Jan-16-26 05:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-14-26 05:10PM	Annexon Maps Pivotal 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead (MarketBeat) +7.92% -7.78%
Jan-12-26 07:00AM	Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 (GlobeNewswire) +5.90%
Jan-08-26 08:00AM	Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barre Syndrome (GlobeNewswire)
Jan-07-26 04:05PM	Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.43%
08:13AM	Loading…
Dec-23-25 08:13AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: AMETEK, Coty, Janus Henderson, Levi Strauss, Pool Corporation, Southern Copper, and More (24/7 Wall St.)
Dec-18-25 01:14AM	Clear Street Asserts Buy Rating on Annexon, Inc. (ANNX) amid Progress on Pipeline Development (Insider Monkey)
Dec-16-25 07:31PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-29-25 01:26AM	Analyst Confidence Strong in Annexon (ANNX) Amid Vonaprument Advancement (Insider Monkey)
Nov-14-25 04:01PM	Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million (GlobeNewswire) +11.44%
Nov-12-25 10:55PM	Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.63%
04:12PM	Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-10-25 04:05PM	Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire)
Sep-30-25 11:41AM	Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition (Insider Monkey)
Aug-27-25 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
04:05PM	Loading…
Aug-18-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.81%
Aug-14-25 04:05PM	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -8.46%
Aug-11-25 07:29AM	Annexon announces EMA selection of vonaprument for PDC pilot participation (Pharmaceutical Business Review)
Aug-07-25 04:30PM	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy (GlobeNewswire)
Jul-24-25 07:00AM	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GlobeNewswire)
Jul-22-25 06:16AM	New Strong Sell Stocks for July 22nd (Zacks)
Jun-18-25 04:05PM	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) (GlobeNewswire)
May-29-25 04:05PM	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +7.39% -6.42%
May-19-25 04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
04:05PM	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting (GlobeNewswire)
May-16-25 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.05%
May-12-25 08:00AM	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) +10.62%
May-09-25 05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire) -5.88%
05:00PM	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting (GlobeNewswire)
May-07-25 08:00AM	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress (GlobeNewswire)
04:05PM	Loading…
Apr-16-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Apr-15-25 07:12AM	Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (Seeking Alpha)
Apr-10-25 09:24AM	Why Annexon Inc. (ANNX) Went Down On Thursday? (Insider Monkey)
Apr-09-25 03:20PM	Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder (Benzinga) -7.79%
Apr-08-25 04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -5.52%
04:05PM	Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Apr-03-25 06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire) -6.63% -7.65%
06:18PM	Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting (GlobeNewswire)
Mar-17-25 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77% -9.09%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Mar-03-25 08:00AM	Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones (GlobeNewswire) -9.47%
Feb-26-25 04:05PM	Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.05%
Feb-13-25 08:30AM	Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting (GlobeNewswire)
Jan-13-25 08:00AM	Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year (GlobeNewswire)
Jan-10-25 08:00AM	Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones (GlobeNewswire)
Jan-07-25 08:00AM	Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.96%
07:30AM	Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS) (GlobeNewswire)
Dec-05-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting (GlobeNewswire)
Nov-19-24 03:00AM	The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate. (Pharma Voice)
Nov-15-24 04:59PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.78%
Nov-14-24 08:00AM	Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Nov-13-24 04:05PM	Annexon Biosciences to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 08:00PM	Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Oct-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 08:00AM	Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting (GlobeNewswire)
Sep-16-24 08:00AM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-09-24 08:00AM	Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress (GlobeNewswire) +8.17%
Sep-03-24 08:00AM	Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio (GlobeNewswire) -5.09%
Aug-29-24 08:00AM	Annexon Biosciences to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-24 08:00AM	Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones (GlobeNewswire)
Aug-05-24 08:00AM	Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy (GlobeNewswire) -9.38%
Jul-16-24 04:05PM	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.02%
Jul-11-24 06:09PM	Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting (GlobeNewswire) +8.53% +11.15%
Jun-29-24 08:48PM	Are Analysts Bullish on Annexon, Inc. (ANNX) Right Now? (Insider Monkey)
Jun-28-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks)
Jun-27-24 09:55AM	Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jun-25-24 05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
05:00PM	Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barr Syndrome at the 2024 PNS Annual Meeting (GlobeNewswire)
Jun-24-24 06:35AM	7 Top Stocks Under $10: June 2024 Edition (InvestorPlace)
Jun-18-24 08:00AM	Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barr Syndrome At 2024 PNS Annual Meeting (GlobeNewswire) -5.41%
Jun-17-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 09:40AM	Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 11:04PM	Annexon Announces Pricing of $125 Million Underwritten Public Offering (GlobeNewswire) +13.36% -13.25%
10:57AM	Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals (Zacks)
09:55AM	Wall Street Analysts Think Annexon (ANNX) Could Surge 133.72%: Read This Before Placing a Bet (Zacks)
04:45AM	Annexons ANX005 offers improvement in Phase III GBS trial (Clinical Trials Arena)
Jun-04-24 05:06PM	Annexon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +30.79%
12:06PM	Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study (Benzinga)
08:46AM	Annexon shares leap as Guillain-Barr drug reduces disability in phase 3 (FierceBiotech.com)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barre Syndrome (GlobeNewswire)
07:00AM	Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barr Syndrome (GlobeNewswire)
Jun-03-24 04:30PM	Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data (GlobeNewswire) -5.18%
May-20-24 09:35AM	Annexon (ANNX) Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +8.08%
May-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-13-24 02:53PM	ANNX Stock Earnings: Annexon Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones (GlobeNewswire)
May-09-24 08:00AM	Annexon Biosciences to Present at the Bank of America Health Care Conference (GlobeNewswire)
May-07-24 12:30PM	Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting (GlobeNewswire)
May-01-24 10:15AM	Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? (Zacks)
08:00AM	Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-25-24 09:35AM	Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) (Zacks)
Apr-17-24 09:40AM	Are Medical Stocks Lagging Annexon (ANNX) This Year? (Zacks) -10.36%
Apr-16-24 04:05PM	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.89%
09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-10-24 06:15PM	Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carson William H.	Director	Dec 30 '25	Buy	5.02	4,115	20,657	54,405	Jan 02 04:30 PM
Choi Jung	Director	Dec 01 '25	Buy	4.19	33,000	138,270	33,000	Dec 03 04:30 PM
Carson William H.	Director	Dec 01 '25	Buy	4.47	4,115	18,394	50,290	Dec 03 04:30 PM
Satter Muneer A	Director	Nov 21 '25	Buy	4.28	422,613	1,808,784	9,728,637	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 20 '25	Buy	4.48	400,000	1,792,000	9,306,024	Nov 21 09:52 PM
Satter Muneer A	Director	Nov 19 '25	Buy	3.94	500,000	1,970,000	8,906,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 18 '25	Buy	3.18	500,000	1,590,000	8,406,024	Nov 19 09:00 PM
Satter Muneer A	Director	Nov 17 '25	Buy	2.99	500,000	1,495,000	7,906,024	Nov 19 09:00 PM
Carson William H.	Director	Oct 30 '25	Buy	3.17	4,115	13,045	46,175	Oct 31 04:15 PM
Carson William H.	Director	Sep 30 '25	Buy	3.05	4,115	12,551	42,060	Oct 02 04:17 PM
Carson William H.	Director	Sep 02 '25	Buy	2.09	4,115	8,600	37,945	Sep 04 04:30 PM
Carson William H.	Director	Jul 30 '25	Buy	2.43	4,115	9,999	33,830	Aug 01 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Jul 14 '25	Sale	2.58	1,116	2,879	105,084	Jul 16 04:20 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Jul 14 '25	Sale	2.58	1,117	2,882	121,616	Jul 16 04:20 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Jul 14 '25	Sale	2.61	853	2,226	130,689	Jul 16 04:20 PM
Yednock Ted	Officer	Jul 14 '25	Proposed Sale	2.58	1,116	2,881		Jul 14 03:51 PM
Overdorf Michael	Officer	Jul 14 '25	Proposed Sale	2.61	853	2,226		Jul 14 03:26 PM
Lew Jennifer	Officer	Jul 14 '25	Proposed Sale	2.58	1,117	2,881		Jul 14 03:17 PM
Carson William H.	Director	Jun 30 '25	Buy	2.46	4,115	10,123	29,715	Jul 01 04:55 PM
Dananberg Jamie	CHIEF MEDICAL OFFICER	Feb 18 '25	Sale	2.96	5,521	16,342	33,479	Feb 20 04:54 PM
ARTIS DEAN RICHARD	EVP & CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	2.97	5,515	16,380	83,814	Feb 20 04:52 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 18 '25	Sale	2.91	8,345	24,284	61,237	Feb 20 04:51 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 18 '25	Sale	2.95	6,618	19,523	86,579	Feb 20 04:49 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 18 '25	Sale	2.92	6,912	20,183	77,770	Feb 20 04:48 PM
Love Douglas	PRESIDENT AND CEO	Feb 13 '25	Sale	2.95	5,021	14,812	351,554	Feb 18 04:30 PM
Lew Jennifer	EVP & CHIEF FINANCIAL OFFICER	Feb 13 '25	Sale	2.98	1,786	5,322	84,682	Feb 18 04:30 PM
Overdorf Michael	EVP & CHIEF BUSINESS OFFICER	Feb 13 '25	Sale	2.99	1,425	4,261	93,197	Feb 18 04:30 PM
Yednock Ted	EVP & CHIEF INNOVATION OFFICER	Feb 13 '25	Sale	2.99	1,783	5,331	69,582	Feb 18 04:30 PM
Yednock Ted	Officer	Feb 18 '25	Proposed Sale	2.91	8,345	24,321		Feb 18 03:21 PM
Lew Jennifer	Officer	Feb 18 '25	Proposed Sale	2.92	8,338	24,319		Feb 18 03:15 PM
ARTIS DEAN RICHARD	Officer	Feb 18 '25	Proposed Sale	2.97	5,515	16,359		Feb 18 03:15 PM
Dananberg Jamie	Officer	Feb 18 '25	Proposed Sale	2.96	5,521	16,359		Feb 18 03:13 PM
Overdorf Michael	Officer	Feb 18 '25	Proposed Sale	2.95	6,618	19,514		Feb 18 03:11 PM
Yednock Ted	Officer	Feb 13 '25	Proposed Sale	2.98	1,783	5,316		Feb 13 03:18 PM
Love Douglas	Officer	Feb 13 '25	Proposed Sale	2.95	5,021	14,799		Feb 13 03:13 PM
Lew Jennifer	Officer	Feb 13 '25	Proposed Sale	2.98	1,786	5,314		Feb 13 03:12 PM
Overdorf Michael	Officer	Feb 13 '25	Proposed Sale	2.99	1,425	4,265		Feb 13 03:06 PM

OLMA

Olema Pharmaceuticals Inc

KYTX

Kyverna Therapeutics Inc

ANNX

Annexon Inc

Upgrade your FINVIZ experience